201 related articles for article (PubMed ID: 15715105)
1. [Experience with therapy of prostate cancer in the Primorye Territory].
Gurina LI; Iudin SV
Vopr Onkol; 2004; 50(5):599-601. PubMed ID: 15715105
[TBL] [Abstract][Full Text] [Related]
2. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
4. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
5. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
6. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Brower V
J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
[No Abstract] [Full Text] [Related]
7. Incidence and management of gynecomastia in men treated for prostate cancer.
Dobs A; Darkes MJ
J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
[TBL] [Abstract][Full Text] [Related]
8. A review of the use of histrelin acetate in the treatment of prostate cancer.
Crawford ED
BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
[No Abstract] [Full Text] [Related]
9. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
10. The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
[No Abstract] [Full Text] [Related]
11. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
12. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
[TBL] [Abstract][Full Text] [Related]
13. Gynecomastia in patients with prostate cancer: update on treatment options.
Autorino R; Perdonà S; D'Armiento M; De Sio M; Damiano R; Cosentino L; Di Lorenzo G
Prostate Cancer Prostatic Dis; 2006; 9(2):109-14. PubMed ID: 16432533
[TBL] [Abstract][Full Text] [Related]
14. Is hormone ablation still the right choice for advanced prostate cancer?
Fitzpatrick JM
BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
[No Abstract] [Full Text] [Related]
15. Tamoxifen for flutamide/finasteride-induced gynecomastia.
Staiman VR; Lowe FC
Urology; 1997 Dec; 50(6):929-33. PubMed ID: 9426725
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
17. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
Kaprin AD; Kostin AA; Tsybul'skiĭ AD
Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
[No Abstract] [Full Text] [Related]
19. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
